Global Recurrent Parotitis Treatment Market
市场规模（十亿美元）
CAGR :
% 
 Forecast Period |
2023 –2030 |
 Market Size (Base Year) |
USD 5,169.56 Million |
 Market Size (Forecast Year) |
USD 8,364.68 Million |
 CAGR |
% |
| Major Markets Players |
>全球复发性腮腺炎治疗市场，按治疗（药物、涎液内镜检查、腮腺切除术、放射治疗、鼓膜神经切除术等）、诊断（X 射线、计算机断层扫描 (CT) 扫描、磁共振成像 (MRI)、涎液造影、超声波检查等）、症状（发烧、腮腺炎症、发红、反复发作时炎症和肿胀复发、疼痛等）、剂量（注射、药片等）、给药途径（口服、肠外、其他）、最终用户（诊所、医院、其他）、分销渠道（医院药房、零售药房、网上药房）– 行业趋势和预测到 2030 年。
复发性腮腺炎治疗市场分析及规模
儿童复发性腮腺炎的发病率较高，估计在儿童人群中发病率为 0.2% 至 5%。男性发病率高于女性，发病年龄通常在 3 至 5 岁之间。成人复发性腮腺炎的发病率低于儿童，但仍有发病的可能。
Data Bridge Market Research 分析，2022 年全球复发性腮腺炎治疗市场规模为 51.6956 亿美元，预计到 2030 年将达到 83.6468 亿美元，预计在 2023-2030 年预测期内的复合年增长率为 6.2%。这表明了市场价值。由于对更好的手术治疗方法的需求不断增长，“手术切除”在复发性全球腮腺炎治疗市场的治疗领域占据主导地位。除了对市场价值、增长率、细分、地理覆盖范围和主要参与者等市场情景的洞察外，Data Bridge Market Research 策划的市场报告还包括深度专家分析、患者流行病学、渠道分析、定价分析和监管框架。
复发性腮腺炎治疗市场范围和细分
|
报告指标 |
细节 |
|
预测期 |
2023 至 2030 年 |
|
基准年 |
2022 |
|
历史岁月 |
2021 (可定制为 2015-2020) |
|
定量单位 |
收入（百万美元）、销量（单位）和定价（美元） |
|
涵盖的领域 |
治疗（药物、涎腺内镜检查、腮腺切除术、放射治疗、鼓膜神经切除术等）、诊断（X 光、计算机断层扫描 (CT)、磁共振成像(MRI)、涎腺造影、超声波检查等）、症状（发烧、腮腺发炎、发红、反复发作的炎症和肿胀、疼痛等）、剂量（注射剂、药片等）、给药途径（口服、肠胃外、其他）、最终用户（诊所、医院、其他）、分销渠道（医院药房、零售药房、网上药房） |
|
覆盖国家 |
U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America |
|
Market Players Covered |
Pfizer Inc. (U.S.), GlaxoSmithKline plc (U.K.), Novartis AG (Switzerland), Sanofi (France), Abbott (U.S.), Bayer AG (Germany), Bristol-Myers Squibb Company (U.S.), F. Hoffmann-La Roche Ltd. (Switzerland), Johnson & Johnson Private Limited (U.S.), Mylan N.V. (U.S.), Allergan (Ireland), Merck & Co., Inc. (U.S.), Melinta Therapeutics LLC (U.S.), Basilea Pharmaceutica Ltd. (Switzerland), Tetraphase Pharmaceuticals (U.S.), Teva Pharmaceutical Industries Ltd. (Israel), Sun Pharmaceutical Industries Ltd. (India), Aurobindo Pharma (India), Lupin (India), SHIONOGI & Co., Ltd. (Japan), AbbVie Inc. (U.S.), Cumberland Pharmaceuticals Inc. (U.S.), Eli Lilly and Company (U.S.), Boehringer Ingelheim International GmbH (Germany), and Takeda Pharmaceutical Company Limited (Japan) |
|
Market Opportunities |
|
Market Definition
The swelling of one or both parotid glands, which are salivary glands positioned in the cheek between the ear and jaw on each side of the head, is known as parotitis. Recurrent parotitis is a recurrent parotid inflammation that is usually linked with non-obstructive parotid gland sialectasis. Recurrent parotitis in children is also termed as juvenile recurrent parotitis. Recurrent episodes of swelling and/or pain in the parotid gland, frequently accompanied by fever and malaise, characterize this condition. It generally affects youngsters, although it can also impact adults. It's a rare ailment, and the cause is yet unknown. Underproduction of saliva, a history of bacterial or viral infections, congenital deformity of the salivary ducts, genetic predisposition, or an underlying autoimmune condition are some of the possibilities being investigated by researchers. Swelling of the parotic glands appears to be caused by a disruption in the usual flow of saliva, which leads to infection of the parotid glands.
Global Recurrent Parotitis Treatment Market Dynamics
Drivers
- Increasing Prevalence of Recurrent Parotitis
The rising incidence of recurrent Parotitis among the population is a major driver for the growth of the treatment market. As more people are diagnosed with the condition, the demand for effective treatment options increases.
- Advancements in Medical Technology
Technological advancements in diagnostic techniques and treatment modalities have improved the accuracy of diagnosis and enhanced the effectiveness of treatment. This has led to increased adoption of treatment options for recurrent Parotitis.
- Rising Demand for Minimally Invasive Procedures
The preference for minimally invasive procedures, such as Sialendoscopy, in the treatment of recurrent Parotitis has increased. These procedures offer less pain, shorter recovery time, and reduced risk of complications, driving their adoption in the market
Opportunities
- Increasing Research and Development
Continued research and development efforts focused on understanding the underlying causes of recurrent Parotitis and developing more effective treatment options can create opportunities for innovative therapies. This includes the exploration of new drug formulations, targeted therapies, and personalized medicine approaches.
- Increasing Technological Advancements
Advancements in medical technology, such as improved imaging techniques and minimally invasive procedures, can enhance the accuracy of diagnosis and effectiveness of treatment. This can create opportunities for the adoption of advanced treatment modalities.
Restraints/Challenges
- High Cost of Treatment
Certain treatment options for recurrent Parotitis, such as Sialendoscopy and surgical interventions, can be expensive. The high cost of these procedures may limit their accessibility, especially in regions with limited healthcare resources or patients with financial constraint.
- Lack of Standardized Treatment Guidelines
There is a lack of standardized treatment guidelines for recurrent Parotitis, leading to variations in treatment approaches among healthcare providers. This can result in inconsistent treatment outcomes and hinder market growth.
- Potential Complications and Adverse Effects
Some treatment options for recurrent Parotitis, such as surgical interventions, carry the risk of complications and adverse effects. This can lead to patient concerns and reluctance to undergo certain treatments, impacting market growth.
- Challenges in Drug Development
Developing new drugs specifically targeting recurrent Parotitis can be challenging due to the complex nature of the condition. Limited research and development in this area may result in a lack of effective pharmacological treatment options.
This global recurrent parotitis treatment market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, the impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the recurrent global parotitis treatment market contact Data Bridge Market Research for an analyst brief, our team will help you make an informed market decision to achieve market growth.
Recent Developments
- In September 2021, Medtronic announced the launch of their new sialendoscopy product, the Medtronic SialoCath™ System, for the treatment of salivary gland disorders including recurrent parotitis. The system offers minimally invasive treatment options for patients
- In August 2021, Sonova Holding AG, a Swiss company specializing in hearing care solutions, announced a collaboration with the University of Zurich to develop a non-invasive treatment for recurrent parotitis using low-intensity focused ultrasound therapy
- In May 2021, Merck KGaA and Artios Pharma Limited announced a research collaboration to develop novel DNA damage response (DDR) targeted therapies for the treatment of various diseases, including recurrent parotitis. The collaboration aims to identify new treatment options based on DDR inhibitors
- In April 2021, Olympus Corporation, a global leader in medical technology, introduced their new EndoTherapy solutions for salivary gland disorders, including recurrent parotitis. The solutions include specialized devices for diagnosis and treatment
Global Recurrent Parotitis Treatment Market Scope
The global recurrent parotitis treatment market is segmented on the basis of treatment, diagnosis, symptoms, dosage, route of administration, end-users and distribution channel. The growth amongst these segments will help you analyse meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.
Treatment
- Medications
- Antibiotics
- Analgesics
- Sialagogues
- Sialoendoscopy
- Parotidectomy
- Radiotherapy
- Tympanic Neurectomy
- Others
- Warm Compresses
- Others
Diagnosis
- X-Ray
- Computed Tomography (CT) Scan
- Magnetic Resonance Imaging (MRI)
- Sialography
- Ultrasonography
- Others
Symptoms
- Fever
- Inflammation of the Parotid Gland
- Redness
- Recurrence of Inflammation and Swelling in Repeated Episodes
- Pain
- Others
Dosage
- Injection
- Tablets
- Others
Route of Administration
- Oral
- Parenteral
- Others
End-Users
- Clinic
- Hospital
- Others
Distribution Channel
- Hospital Pharmacy
- Retail Pharmacy
- Online Pharmacy
Global Recurrent Parotitis Treatment Market Regional Analysis/Insights
The global parotitis treatment market is analysed and market size insights and trends are provided by country, treatment, diagnosis, symptoms, dosage, route of administration, end-users and distribution channel as referenced above.
The countries covered in the global recurrent parotitis treatment market report are U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America
North America dominates the global recurrent parotitis treatment market because of the strong base of healthcare facilities, the strong presence of major players in the market, the extraordinary healthcare infrastructure, and the large pool of people having recurrent parotitis.
Asia-Pacific is expected to witness significant growth during the forecast period of 2023 to 2030 due to the increase in government initiatives to promote healthcare, the rising health awareness among the people and growing demand for advanced medical technology for treatment and diagnosis, the large population pool, and the growing demand for quality healthcare in the region.
The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impact the current and future trends of the market. Data points like down-stream and upstream value chain analysis, technical trends, and porter's five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, the impact of domestic tariffs, and trade routes are considered while providing forecast analysis of the country data.
Healthcare Infrastructure Growth Installed Base and New Technology Penetration
The global recurrent parotitis treatment market also provides you with a detailed market analysis for every country's growth in healthcare expenditure for capital equipment, installed base of different kinds of products for the global recurrent parotitis treatment market, the impact of technology using lifeline curves and changes in healthcare regulatory scenarios and their impact on the global recurrent parotitis treatment market. The data is available for the historic period 2015-2020
Competitive Landscape and Global Recurrent Parotitis Treatment Market Share Analysis
全球复发性腮腺炎治疗市场竞争格局提供了竞争对手的详细信息。详细信息包括公司概况、公司财务状况、产生的收入、市场潜力、研发投资、新市场计划、全球影响力、生产基地和设施、生产能力、公司优势和劣势、产品发布、产品宽度和广度、应用主导地位。以上提供的数据点仅与公司对全球复发性腮腺炎治疗市场的关注有关。
全球复发性腮腺炎治疗市场的一些主要参与者包括：
- 辉瑞公司（美国）
- 葛兰素史克公司 (英国)
- 诺华公司（瑞士）
- 赛诺菲（法国）
- 雅培（美国）
- 拜耳公司（德国）
- 百时美施贵宝公司 (美国)
- F. Hoffmann-La Roche Ltd.（瑞士）
- 强生私人有限公司（美国）
- Mylan NV（美国）
- 艾尔建（爱尔兰）
- 默克公司（美国）
- Melinta Therapeutics LLC（美国）
- 巴塞利亚制药有限公司 (瑞士)
- Tetraphase Pharmaceuticals（美国）
- Teva Pharmaceutical Industries Ltd.（以色列）
- 太阳制药工业有限公司 (印度)
- Aurobindo Pharma（印度）
- Lupin（印度）、SHIONOGI & Co., Ltd.（日本）
- AbbVie Inc.（美国）
- 坎伯兰制药公司（美国）
- 礼来公司 (美国)
- 勃林格殷格翰国际有限公司 (德国)
- 武田药品工业株式会社 (日本)
SKU-
Get online access to the report on the World's First Market Intelligence Cloud
- Interactive Data Analysis Dashboard
- Company Analysis Dashboard for high growth potential opportunities
- Research Analyst Access for customization & queries
- Competitor Analysis with Interactive dashboard
- Latest News, Updates & Trend analysis
- Harness the Power of Benchmark Analysis for Comprehensive Competitor Tracking
研究方法
Data collection and base year analysis are done using data collection modules with large sample sizes. The stage includes obtaining market information or related data through various sources and strategies. It includes examining and planning all the data acquired from the past in advance. It likewise envelops the examination of information inconsistencies seen across different information sources. The market data is analysed and estimated using market statistical and coherent models. Also, market share analysis and key trend analysis are the major success factors in the market report. To know more, please request an analyst call or drop down your inquiry.
The key research methodology used by DBMR research team is data triangulation which involves data mining, analysis of the impact of data variables on the market and primary (industry expert) validation. Data models include Vendor Positioning Grid, Market Time Line Analysis, Market Overview and Guide, Company Positioning Grid, Patent Analysis, Pricing Analysis, Company Market Share Analysis, Standards of Measurement, Global versus Regional and Vendor Share Analysis. To know more about the research methodology, drop in an inquiry to speak to our industry experts.
可定制
Data Bridge Market Research is a leader in advanced formative research. We take pride in servicing our existing and new customers with data and analysis that match and suits their goal. The report can be customized to include price trend analysis of target brands understanding the market for additional countries (ask for the list of countries), clinical trial results data, literature review, refurbished market and product base analysis. Market analysis of target competitors can be analyzed from technology-based analysis to market portfolio strategies. We can add as many competitors that you require data about in the format and data style you are looking for. Our team of analysts can also provide you data in crude raw excel files pivot tables (Fact book) or can assist you in creating presentations from the data sets available in the report.
